Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma

BACKGROUND: Lapatinib, a dual EGFR and HER2 inhibitor has shown disappointing results in clinical trials of metastatic oesophago-gastric adenocarcinomas (OGAs), and in vitro studies suggest that MET, IGFR, and HER3 confer resistance. This trial applied Lapatinib in the curative neoadjuvant setting a...

Descripción completa

Detalles Bibliográficos
Autores principales: De Silva, Nadeera, Schulz, Laura, Paterson, Anna, Qain, Wendi, Secrier, Maria, Godfrey, Edmund, Cheow, Heok, O'Donovan, Maria, Lao-Sirieix, Pierre, Jobanputra, Minesh, Hochhauser, Daniel, Fitzgerald, Rebecca, Ford, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815800/
https://www.ncbi.nlm.nih.gov/pubmed/26484410
http://dx.doi.org/10.1038/bjc.2015.342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815800/
https://www.ncbi.nlm.nih.gov/pubmed/26484410
http://dx.doi.org/10.1038/bjc.2015.342

Ejemplares similares